It's a fact of life for pharmaceutical companies without a pipeline full of drug candidates that they'll eventually go bust because of generic competition. They can either invest more in research and development or get licenses for and become partners with other companies for novel drug candidates. Thursday morning, Motley FoolStock Advisor pick BiogenIdec
In a deal worth $42.5 million (including a $5 million equity investment), Biogen bought the rights to an inhaled pulmonary arterial hypertension drug (PAH) named Aviptadil from privately held Swiss biotech mondoBIOTECH. Aviptadil is in early stage clinical trials. If the drug is eventually approved, Biogen would take over all of its testing and sales.
In the past two years, Biogen has been very active in bolstering its pipeline. It has signed partnership deals with mondoBIOTECH and Rule Breakers recommendation PDLBioPharma
For Rule Breakers subscribers, PAH -- a type of high blood pressure -- should sound familiar because that's the disease that another newsletter selection, EncysivePharmaceuticals
Even making the huge assumption that Aviptadil could show that it's as effective as Thelin or Ambrisentan in treating PAH, the drug would serve a different patient group because it's an inhalation therapy. As I've said on the Rule Breakers discussion boards, I don't think Encysive investors should worry too much about the imagined superiority of competing drugs.
It would take Biogen many years to commercialize Aviptadil even if the drug makes it through the regulatory process. If Aviptadil can carve out a niche and compete with the other treatments for PAH, then the $42.5 million that Biogen paid for the drug would be a steal, because treating PAH could be worth well over a billion dollars to companies.
Ordinarily, I'd be a little wary of biotech companies that have run out of in-house drug candidates and are forced to scour the market for new drugs. Biogen, though, has had a long and successful history of filling out its pipeline via acquisitions of drug candidates and then successfully commercializing them.
What stocks are at the top of Tom and David Gardner's list? Be our guest at the Stock Advisor website for 30 days and find out.
More from The Motley Fool
Will 2018 Be Biogen Inc.'s Best Year Yet?
You probably don't want to bet the farm on it.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Biogen Inc. Buys Its Way Out of Competition
The big biotech gains rights to a potential Tecfidera competitor from Alkermes.